RU2014134845A - Терапевтическое средство против диабета - Google Patents

Терапевтическое средство против диабета Download PDF

Info

Publication number
RU2014134845A
RU2014134845A RU2014134845A RU2014134845A RU2014134845A RU 2014134845 A RU2014134845 A RU 2014134845A RU 2014134845 A RU2014134845 A RU 2014134845A RU 2014134845 A RU2014134845 A RU 2014134845A RU 2014134845 A RU2014134845 A RU 2014134845A
Authority
RU
Russia
Prior art keywords
therapeutic
group
impaired glucose
prophylactic agent
glucose metabolism
Prior art date
Application number
RU2014134845A
Other languages
English (en)
Russian (ru)
Inventor
Итиро ХИСАТОМЭ
Сунсукэ ЦУДЗИМОТО
Такаси СИРАКУРА
Синя ХИРАМИЦУ
Original Assignee
Тейдзин Фарма Лимитед
Нэшнл Юниверсити Корпорейшн Тоттори Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тейдзин Фарма Лимитед, Нэшнл Юниверсити Корпорейшн Тоттори Юниверсити filed Critical Тейдзин Фарма Лимитед
Publication of RU2014134845A publication Critical patent/RU2014134845A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014134845A 2012-01-27 2013-01-25 Терапевтическое средство против диабета RU2014134845A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
JP2012-015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
RU2014134845A true RU2014134845A (ru) 2016-03-20

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014134845A RU2014134845A (ru) 2012-01-27 2013-01-25 Терапевтическое средство против диабета

Country Status (15)

Country Link
US (1) US20150005506A1 (enExample)
EP (1) EP2808018B1 (enExample)
JP (1) JP5924699B2 (enExample)
KR (1) KR20140134266A (enExample)
CN (1) CN104066430A (enExample)
AR (1) AR089812A1 (enExample)
AU (1) AU2013212865A1 (enExample)
BR (1) BR112014017902A2 (enExample)
CA (1) CA2862602A1 (enExample)
HK (1) HK1201209A1 (enExample)
IN (1) IN2014DN05972A (enExample)
MX (1) MX2014008484A (enExample)
RU (1) RU2014134845A (enExample)
TW (1) TW201334779A (enExample)
WO (1) WO2013111870A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
CN109069490B (zh) 2016-02-19 2021-07-16 上海根乃津药业科技有限公司 痴呆症治疗药或预防药

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (de) * 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
AU2006276933A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
EP1957064A4 (en) * 2005-11-21 2010-01-06 Tap Pharmaceutical Prod Inc TREATMENT OF QT INTERVAL EXTENSION AND RELEVANT DISEASES
JP2007210978A (ja) * 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ii型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
BRPI0718611A2 (pt) 2006-11-13 2014-02-25 Takeda Pharmaceuticals North America Inc Métodos para preservar a função renal utilizando inibidores da xantina oxidoredutase.
DK2217577T3 (da) * 2007-11-27 2014-10-20 Ardea Biosciences Inc Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
JP5314123B2 (ja) * 2008-03-31 2013-10-16 シー アンド シー リサーチ ラボラトリーズ 複素環誘導体
US8410154B2 (en) * 2008-04-30 2013-04-02 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
JP5820269B2 (ja) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物
EP2398319A4 (en) * 2008-10-19 2012-11-14 Richard J Johnson THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CHRONIC NEPHITIA ASSOCIATED WITH METABOLIC IMBALANCE
WO2011022757A1 (en) * 2009-08-24 2011-03-03 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
RU2602188C2 (ru) * 2010-06-16 2016-11-10 Такеда Фармасьютикалз Ю.Эс.Эй.,Инк. Фармацевтическая композиция с модифицированным высвобождением, включающая фебуксостат
AR082022A1 (es) * 2010-06-25 2012-11-07 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Also Published As

Publication number Publication date
HK1201209A1 (en) 2015-08-28
WO2013111870A1 (ja) 2013-08-01
EP2808018A4 (en) 2015-07-15
AR089812A1 (es) 2014-09-17
AU2013212865A1 (en) 2014-08-14
KR20140134266A (ko) 2014-11-21
MX2014008484A (es) 2014-10-14
JPWO2013111870A1 (ja) 2015-05-11
TW201334779A (zh) 2013-09-01
US20150005506A1 (en) 2015-01-01
CN104066430A (zh) 2014-09-24
JP5924699B2 (ja) 2016-05-25
BR112014017902A2 (pt) 2017-08-22
EP2808018B1 (en) 2018-03-14
CA2862602A1 (en) 2013-08-01
IN2014DN05972A (enExample) 2015-06-26
EP2808018A1 (en) 2014-12-03

Similar Documents

Publication Publication Date Title
RU2014134845A (ru) Терапевтическое средство против диабета
EP1857457A3 (en) Benzimidazole derivative and its use as AII receptor antagonist
NZ601121A (en) 5-alkynyl-pyrimidines
JP2015518491A5 (enExample)
NZ609309A (en) Redox drug derivatives
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
MX358679B (es) Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
ME02312B (me) DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE
EA201491671A1 (ru) Гетероциклильные соединения
AR055060A1 (es) Derivados de n-(piridin-2-il)-sulfonamida
NZ607580A (en) N-heteroaryl compounds
RU2015117251A (ru) Новые соединения
JP2012520342A5 (enExample)
JP2018502101A5 (enExample)
NZ603465A (en) Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
JP2012512863A5 (enExample)
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
WO2010010288A3 (fr) Derives de carbamates d' alkylthiazoles, leur preparation et leur utilisation comme inhbiteurs de l'enzyme faah
RU2011121809A (ru) Производное циклогексана и его фармацевтическое применение
NZ602450A (en) Agomelatine hydrochloride hydrate and preparation thereof
AR092960A1 (es) Procedimiento para preparar compuestos tienopirimidina
RU2015117647A (ru) Новые производные пиразола
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160830